The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients

Sun,W.; Sun,Y.; Zhu,M.; Wang,Z.; Zhang,H.; Xin,Y.; Jiang,G.; Guo,X.; Zhang,Z.; Liu,Y.

doi:10.3892/or.2013.2949

The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients

Authors:
- W. Sun
- Y. Sun
- M. Zhu
- Z. Wang
- H. Zhang
- Y. Xin
- G. Jiang
- X. Guo
- Z. Zhang
- Y. Liu
View Affiliations

Affiliations: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, Cancer Research Institute of Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Published online on: December 30, 2013 https://doi.org/10.3892/or.2013.2949
Pages: 1466-1472

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, we studied the relationship between plasma cell-free DNA and the effect of preoperative chemoradiotherapy in patients with rectal cancer. The concentration, KRAS mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status of cell-free DNA were measured by using polymerase chain reaction (PCR) analyses. The response to chemoradiotherapy was assessed using tumor regression grading (TRG) scores. The cell-free DNA concentrations in patients with rectal cancer (n=34) were significantly higher compared to healthy controls (n=10). The 400-base pair (bp) DNA concentration, 400-/100-bp DNA ratio decreased significantly after chemoradiotherapy in the good response group. The incidence of KRAS mutation decreased significantly after chemoradiotherapy in both good and poor response groups. Higher MGMT promoter methylation status at baseline DNA was associated with a better tumor response. Therefore, cell-free DNA detection may be useful in evaluating the effect of preoperative chemoradiotherapy in patients with rectal cancer.

View Figures

View References

1	Tural D, Ozturk M, Selcukbiricik F, et al: Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. J BUON. 18:385–390. 2013.PubMed/NCBI
2	Valentini V, Coco C, Picciocchi A, et al: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 53:664–674. 2002. View Article : Google Scholar
3	Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, et al: A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics J. 11:437–443. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wong MT, Lim JF, Ho KS, et al: Radiation proctitis: a decade’s experience. Singapore Med J. 51:315–319. 2010.
5	Torres-Roca JF and Stevens CW: Predicting response to clinical radiotherapy: past, present, and future directions. Cancer Control. 15:151–156. 2008.PubMed/NCBI
6	Benn P, Cuckle H and Pergament E: Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 42:15–33. 2013. View Article : Google Scholar : PubMed/NCBI
7	Liao GJ, Chiu RW and Lo YM: Prenatal assessment of fetal chromosomal and genetic disorders through maternal plasma DNA analysis. Pathology. 44:69–72. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hahn S, Rusterholz C, Hösli I and Lapaire O: Cell-free nucleic acids as potential markers for preeclampsia. Placenta. 32(Suppl 1): S17–S20. 2011. View Article : Google Scholar : PubMed/NCBI
9	De Mattos-Arruda L, Cortes J, Santarpia L, et al: Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol. 10:377–389. 2013.PubMed/NCBI
10	Ghorbian S and Ardekani AM: Non-invasive detection of esophageal cancer using genetic changes in circulating cell-free DNA. Avicenna J Med Biotechnol. 4:3–13. 2012.PubMed/NCBI
11	Kamat AA, Baldwin M, Urbauer D, et al: Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 116:1918–1925. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ellinger J, Müller SC, Stadler TC, et al: The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol. 29:124–129. 2011. View Article : Google Scholar : PubMed/NCBI
13	van der Vaart M and Pretorius PJ: The origin of circulating free DNA. Clin Chem. 53:22152007.PubMed/NCBI
14	Lecomte T, Berger A, Zinzindohoué F, et al: Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 100:542–548. 2002. View Article : Google Scholar : PubMed/NCBI
15	Cheng C, Omura-Minamisawa M, Kang Y, et al: Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci. 100:303–309. 2009. View Article : Google Scholar : PubMed/NCBI
16	Agostini M, Pucciarelli S, Enzo MV, et al: Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy. Ann Surg Oncol. 18:2461–2468. 2011. View Article : Google Scholar
17	Mulcahy HE, Lyautey J, Lederrey C, et al: A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res. 4:271–275. 1998.PubMed/NCBI
18	Koutsimpelas D, Pongsapich W, Heinrich U, et al: Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: Pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncol Rep. 27:1135–1141. 2012.
19	Dworak O, Keilholz L and Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
20	Sameer AS: Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 3:1142013. View Article : Google Scholar : PubMed/NCBI
21	Gagliardi G, Biricotti M, Failli A, et al: Colorectal carcinoma and folate. Ann Ital Chir. 84:123–131. 2013.PubMed/NCBI
22	Wong RK, Tandan V, De Silva S and Figueredo A: Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev. 2:CD0021022007.PubMed/NCBI
23	Kilic D, Yalman D, Aksu G, et al: Impact of adjuvant chemoradiotherapy for rectal cancer on the long-term quality of life and late side effects: a multicentric clinical evaluation by the Turkish Oncology Group. Asian Pac J Cancer Prev. 13:5741–5746. 2012. View Article : Google Scholar : PubMed/NCBI
24	De Caluwé L, Van Nieuwenhove Y and Ceelen WP: Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2:CD0060412013.
25	González-Masiá JA, García-Olmo D and García-Olmo DC: Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 6:819–832. 2013.PubMed/NCBI
26	Gorges TM, Schiller J, Schmitz A, et al: Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA. Biomarkers. 17:498–506. 2012. View Article : Google Scholar : PubMed/NCBI
27	Mouliere F, Robert B, Arnau Peyrotte E, et al: High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 6:e234182011. View Article : Google Scholar : PubMed/NCBI
28	Thierry AR, Mouliere F, Gongora C, et al: Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 38:6159–6175. 2010. View Article : Google Scholar : PubMed/NCBI
29	Mouliere F and Thierry AR: The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. Expert Opin Biol Ther. 12(Suppl 1): S209–S215. 2012. View Article : Google Scholar : PubMed/NCBI
30	Zitt M, Müller HM, Rochel M, et al: Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. 25:159–165. 2008. View Article : Google Scholar
31	Zitt M, Zitt M, Müller HM, et al: Disseminated tumor cells in peripheral blood: a novel marker for therapy response in locally advanced rectal cancer patients undergoing preoperative chemoradiation. Dis Colon Rectum. 49:1484–1491. 2006. View Article : Google Scholar
32	Liggett TE, Melnikov AA, Marks JR and Levenson VV: Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer. 128:492–499. 2011. View Article : Google Scholar : PubMed/NCBI
33	Jing R, Cui M, Wang H and Ju S: Cell-free DNA: characteristics, detection and its applications in myocardial infarction. Curr Pharm Des. 19:5135–5145. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lilleberg SL, Durocher J, Sanders C, et al: High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. Ann NY Acad Sci. 1022:250–256. 2004. View Article : Google Scholar
35	Wang JY, Hsieh JS, Chang MY, et al: Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 28:721–726. 2004.
36	Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486:532–536. 2012.
37	Dobrzycka B, Terlikowski SJ, Mazurek A, et al: Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma. Folia Histochem Cytobiol. 47:65–68. 2009. View Article : Google Scholar : PubMed/NCBI
38	Dobrzycka B, Terlikowski SJ, Mazurek A, et al: Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer. 127:612–621. 2010. View Article : Google Scholar : PubMed/NCBI
39	Roberts PJ and Stinchcombe TE: KRAS mutation: should we test for it, and does it matter? J Clin Oncol. 31:1112–1121. 2013. View Article : Google Scholar
40	Morgan SR, Whiteley J, Donald E, et al: Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol. 5:15–22. 2012.
41	Nygaard AD, Garm Spindler KL, Pallisgaard N, et al: The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 79:312–317. 2013. View Article : Google Scholar : PubMed/NCBI
42	Spindler KL, Pallisgaard N, Vogelius I and Jakobsen A: Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 18:1177–1185. 2012.
43	Fukushima T, Takeshima H and Kataoka H: Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 29:4845–4854. 2009.PubMed/NCBI
44	Psofaki V, Kalogera C, Tzambouras N, et al: Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J Gastroenterol. 16:3553–3560. 2010. View Article : Google Scholar : PubMed/NCBI
45	Rivera AL, Pelloski CE, Gilbert MR, et al: MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 12:116–121. 2010. View Article : Google Scholar : PubMed/NCBI